We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced that the phase III REACH2 study, which evaluated Jakavi (ruxolitinib) for treating patients with steroid-refractory acute graft-versus-host disease (GVHD), has met the primary endpoint.
The study met the primary endpoint of superior overall response rate (ORR) following treatment with Jakavi compared to the best available therapy at day 28.
The positive result from the study will be the basis of regulatory submissions seeking approval of Jakavi for the above-mentioned indication in Europe and other countries. Further analysis of the safety and efficacy data is currently ongoing.
Novartis plans to begin discussions with ex-U.S. regulatory authorities in 2020 regarding the drug’s marketing application.
Jakavi is marketed in the United States as Jakafi by Incyte Corporation (INCY - Free Report) .
Meanwhile, a phase III REACH3 study evaluating Jakavi/Jakafi for addressing patients with steroid-refractory chronic GVHD is currently underway. The study is co-sponsored by Incyte and Novartis and data from the same is expected next year.
Shares of Novartis have inched up 1.4% so far this year compared with the industry’s increase of 0.2%.
Notably in May 2019, the FDA approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or older.
The approval was based on encouraging data from REACH1, an open-label, single-arm, multicenter study of Jakafi in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD.
Jakafi, a first-in-class JAK1/JAK2 inhibitor, is approved in the United States for the treatment of patients with polycythemia vera (PV), who had an inadequate response to or are intolerant to hydroxyurea. The drug also won the nod for treating patients with intermediate or high-risk myelofibrosis (MF) including primary MF, post-PV MF and post-essential thrombocythemia MF.
GlaxoSmithKline’s earnings estimates have been revised 2.1% upward for 2019 and 0.3% for 2020 over the past 60 days. The stock has rallied 10.6% year to date.
AbbVie’s earnings estimates have moved 0.7% north for 2019 and 0.8% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
Novartis AG (NVS - Free Report) announced that the phase III REACH2 study, which evaluated Jakavi (ruxolitinib) for treating patients with steroid-refractory acute graft-versus-host disease (GVHD), has met the primary endpoint.
The study met the primary endpoint of superior overall response rate (ORR) following treatment with Jakavi compared to the best available therapy at day 28.
The positive result from the study will be the basis of regulatory submissions seeking approval of Jakavi for the above-mentioned indication in Europe and other countries. Further analysis of the safety and efficacy data is currently ongoing.
Novartis plans to begin discussions with ex-U.S. regulatory authorities in 2020 regarding the drug’s marketing application.
Jakavi is marketed in the United States as Jakafi by Incyte Corporation (INCY - Free Report) .
Meanwhile, a phase III REACH3 study evaluating Jakavi/Jakafi for addressing patients with steroid-refractory chronic GVHD is currently underway. The study is co-sponsored by Incyte and Novartis and data from the same is expected next year.
Shares of Novartis have inched up 1.4% so far this year compared with the industry’s increase of 0.2%.
Notably in May 2019, the FDA approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or older.
The approval was based on encouraging data from REACH1, an open-label, single-arm, multicenter study of Jakafi in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD.
Jakafi, a first-in-class JAK1/JAK2 inhibitor, is approved in the United States for the treatment of patients with polycythemia vera (PV), who had an inadequate response to or are intolerant to hydroxyurea. The drug also won the nod for treating patients with intermediate or high-risk myelofibrosis (MF) including primary MF, post-PV MF and post-essential thrombocythemia MF.
Zacks Rank & Stocks to Consider
Novartis currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the large-cap pharma sector include GlaxoSmithKline plc (GSK - Free Report) and AbbVie Inc. (ABBV - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GlaxoSmithKline’s earnings estimates have been revised 2.1% upward for 2019 and 0.3% for 2020 over the past 60 days. The stock has rallied 10.6% year to date.
AbbVie’s earnings estimates have moved 0.7% north for 2019 and 0.8% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>